The cost of failure

Surgical Infections

Volumn 9, Issue 3, 2008, Pages 313-315

  Barie, Philip S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; SULPERAZON;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; CLINICAL TRIAL; COST CONTROL; DISEASE SEVERITY; EDITORIAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HEALTH CARE COST; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REOPERATION; RISK FACTOR; SURGICAL INFECTION; TREATMENT FAILURE;

ABDOMEN; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HEALTH CARE COSTS; HUMANS; TREATMENT FAILURE;

EID: 45749116160     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.9964     Document Type: Editorial

References (28)

1. Schein M, Marshall J. Source control for surgical infections. World J Surg 2004;28:638-645.
2. Anaya DA, Nathens AB. Risk factors for severe sepsis in secondary peritonitis. Surg Infect 2003;4:355-362.
3. Mazuski JE. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007;8:2933-2945.
4. Mazuski JE, Sawyer RG, Nathens AB, et al. Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect 2002;3:161-173.
5. Mazuski JE, Sawyer RG, Nathens AB, et al. Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect 2002;3:175-233.
6. Barie PS. Oh Lord! I've got those clinical research blues. Surg Infect 2004;5:327-342.
7. Barie PS, Hydo LJ, Eachempati SR. Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg Infect 2004;5:365-373.
8. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294-1302.
9. Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: Equal to the challenge? Surg Infect 2002;3:315-335.
10. Pieracci FM, Barie PS. Management of severe sepsis of abdominal origin. Scand J Surg 2007;96:184-196.
11. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-494.
12. Roehrborn A, Thomas L, Potreck O, et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-1519.
13. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect 2007;8:159-172.
14. Ohmann C, Yang Q, Hau T, Wacha H. Prognostic modelling in peritonitis. Peritonitis Study Group of the Surgical Infection Society Europe. Eur J Surg 1997;163:53-60.
15. Suding PN, Orrico RP, Johnson SB, Wilson SE. Concordance of interrater assessments of surgical methods to achieve source control of intra-abdominal infections. Am J Surg 2008 Apr 22. [Epub ahead of print]
16. Tellado JM. The need for new antimicrobials for intra-abdominal infections (IAI): defining the forthcoming scenario. Surg Infect 2006;7:1-4.
17. Stelling JM, Travers K, Jones RN, et al. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis 2005;11:873-882.
18. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166.
19. Dortet L, Radu I, Gautier V, et al. Intercontinental travels of patients and dissemination of plasmid-mediated carbapenemase KPC-3 associated with OXA-9 and TEM-1. J Antimicrob Chemother 2008;61:455-457.
20. Gottesman T, Agmon O, Shwartz O, Dan M. Household transmission of carbapenemase-producing Klebsiella pneumoniae. Emerg Infect Dis 2008;14:859-60.
21. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005 Jun;55:965-973.
22. Bochicchio GV, Baquero F, Hsueh PR, et al. In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: Results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg Infect 2006;7:537-545.
23. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gramnegative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-210.
24. Wilcox MH. Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect 2006;7:69-80.
25. Eagye KJ, Kuti JL, Nicolau DP. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect 2007;8:215-226.
26. Edelsberg J Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect 2008;9:335-347.
27. Barie PS, Rotstein OD, Dellinger EP, Grasela TH, Walawander CA. The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection. Surg Infect 2004;5:269-280.
28. MASCOT Study Group. Chandra A, Dhar P, Dharap S, et al. Cefoperazone-sulbactam for treatment of intra-abdominal infections: Results from a randomized, parallel group study in India. Surg Infect 2008;9:367-376.